Novan to Report Full Year 2022 Financial Results on March 30, 2023

Rhea-AI Summary

Novan, Inc. (Nasdaq: NOVN) announced that it will release its full year 2022 financial results on March 30, 2023, followed by a conference call at 8:30 a.m. ET. The call will be led by President and CEO Paula Brown Stafford, with other management members participating. Investors can join via phone or live audio webcast on Novan's website, which will remain archived for 90 days.

Novan, a medical dermatology company, focuses on innovative therapies for skin diseases, including an FDA filing for berdazimer gel for molluscum contagiosum. The company leverages its nitric oxide-based technology platform, NITRICIL™, to develop new treatments.

Positive

• Expected conference call to discuss full year 2022 financial results, potentially positive for investor sentiment.
• FDA acceptance of Novan's NDA for berdazimer gel indicates progress in product development.

Negative

• None.

DURHAM, N.C., March 23, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its full year 2022 financial results on Thursday, March 30^th. Novan management will host a conference call and live audio webcast to discuss the operational and financial results at 8:30 a.m. ET that same day.

The call will be led by Paula Brown Stafford, President and Chief Executive Officer of Novan, who will be joined by additional members of the Novan management team. Interested participants and investors may access the conference call by dialing (833) 630-1956 (domestic) or (412) 317-1837 (international) and referencing the Novan, Inc. Conference Call. The live webcast will be accessible on the Events page of the Investors section of the Novan website, novan.com, and will be archived for 90 days.

About Novan

Novan, Inc. is a medical dermatology company primarily focused on developing and commercializing innovative therapeutic products for skin diseases. Our goal is to deliver safe and efficacious therapies to patients, including developing product candidates where there are unmet medical needs. Novan has a robust commercial infrastructure across sales, marketing, and communications, as well as fully dedicated market access and pharmacy relation teams, promoting products for plaque psoriasis, rosacea and acne. The U.S. Food and Drug Administration (“FDA”) accepted for filing Novan’s New Drug Application (“NDA”) seeking approval for berdazimer gel, 10.3% (SB206) for the treatment of molluscum contagiosum. The Company also has a pipeline of potential product candidates using its proprietary nitric oxide-based technology platform, NITRICIL™, to generate new treatments for multiple indications.

INVESTOR AND MEDIA CONTACT:

Jenene Thomas
JTC Team, LLC
833-475-8247
NOVN@jtcir.com

FAQ

When will Novan report its full year 2022 financial results?

Novan will report its full year 2022 financial results on March 30, 2023.

What time is Novan's conference call for the financial results?

The conference call is scheduled for 8:30 a.m. ET on March 30, 2023.

How can I access Novan's conference call?

Interested participants can access the conference call by dialing (833) 630-1956 for domestic calls or (412) 317-1837 for international calls.

What product is Novan seeking FDA approval for?

Novan is seeking FDA approval for berdazimer gel, 10.3% (SB206), for the treatment of molluscum contagiosum.

What technologies does Novan use for product development?

Novan utilizes its proprietary nitric oxide-based technology platform, NITRICIL™, to develop new treatments.